|
CCND3 rs2479717 genotype frequency across stage, grade, and estrogen receptor status |
||||
| CCND3 rs2479717 genotype |
||||
| AA |
AT |
TT |
Missing |
|
|
|
||||
| Stage |
||||
| 1 |
1,193 (54.5%) |
808 (36.9%) |
142 (6.5%) |
48 (2.2%) |
| 2 |
1,031 (52.0%) |
753 (38.0%) |
145 (7.3%) |
54 (2.7%) |
| 3 or 4 |
90 (46.4%) |
82 (42.3%) |
17 (8.8%) |
5 (2.6%) |
| Missing |
60 (58.8%) |
31 (30.4%) |
9 (8.8%) |
2 (2.0%) |
| Grade |
||||
| 1 |
484 (55.4%) |
314 (35.9%) |
60 (6.9%) |
16 (1.8%) |
| 2 |
889 (52.7%) |
658 (39.0%) |
104 (6.2%) |
36 (2.1%) |
| 3 |
533 (52.3%) |
375 (36.8%) |
86 (8.4%) |
26 (2.5%) |
| Missing |
468 (52.5%) |
327 (36.7%) |
63 (7.1%) |
34 (3.8%) |
| Estrogen receptor status |
||||
| Positive |
1,089 (55.1%) |
717 (36.3%) |
130 (6.6%) |
39 (2.0%) |
| Negative |
320 (49.3%) |
262 (40.4%) |
53 (8.2%) |
14 (2.2%) |
| Missing |
965 (52.3%) |
695 (37.6%) |
130 (7.0%) |
56 (3.0%) |
Azzato et al. Breast Cancer Research 2008 10:R47 doi:10.1186/bcr2100 |
||||